# A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

> **NCT03572062** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 317 (actual)

## Conditions studied

- Respiratory Tract Infection

## Interventions

- **BIOLOGICAL:** Formulation A
- **BIOLOGICAL:** Formulation B
- **BIOLOGICAL:** Formulation C
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03572062
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-05
- **Primary completion:** 2020-06-23
- **Final completion:** 2020-08-19
- **Target enrollment:** 317 (ACTUAL)
- **Why stopped:** Study halted prematurely by sponsor and will not resume, participants are no longer being examined or receiving intervention.
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572062, "A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03572062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*